21. Februar 2024
Published by Paul Wolfrom on 21. Februar 2024
Categories

LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V

Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further […]
Do you like it?0
Read more
1. Februar 2024
Published by Paul Wolfrom on 1. Februar 2024
Categories

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raise to $40 Million

Schlieren (Zurich), February 01, 2024 – LimmaTech Biologics today announced a second closing of its Series A financing, raising an additional USD 3 million from new […]
Do you like it?0
Read more
19. Dezember 2023
Published by Paul Wolfrom on 19. Dezember 2023
Categories

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

LimmaTech receives an exclusive clinical development license from AbVacc for a multivalent, toxoid vaccine candidate to prevent infections caused by Staphylococcus aureus, the leading cause of […]
Do you like it?0
Read more
9. Oktober 2023
Published by Paul Wolfrom on 9. Oktober 2023
Categories

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Schlieren (Zurich), October 9, 2023 – LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led […]
Do you like it?0
Read more
1234567
Next page